"Citron's reports are a lot more fun to read than just about anything published by a mainstream Wall Street stock analyst."
-- Bloomberg News

Sep. 29, 2015
HomeReportsArchivesContact Us / SuggestionsLegal DisclaimerWho is Citron

Why a Congressional Subpoena to Valeant About Price Gouging on Drugs Should be Granted

Posted in Citron Reports by Stocklemon on the September 28th, 2015

The Real Risk to the US Healthcare System is when Health Care Costs are controlled by Hedge Fund Billionaires

How Pharmaceutical Pricing Runs Amok While U.S. Taxpayers Are Looted

As well as a major threat to the integrity of our entire healthcare system, Valeant (NYSE:VRX) is now the most devious three-cornered tax avoidance scheme we've ever seen.  

For the Story you Won't Read Anywhere Else, Click Here…




How the Volkswagen Scandal PROVES Citron’s Analysis of Mobileye

Posted in Citron Reports by Stocklemon on the September 24th, 2015

Citron Lowers Near Term Target to $20: See GPRO and AMBA

The biggest story in the business world over the past week has been Volkswagen’s emissions cheating scandal.  But the analysis that has gone overlooked by the media.  The looming question not dissected in the press, nor answered by the automotive markets analyst community is not what Volkswagen did, but WHY they did it.

Citron shows how the Volkswagen debacle places in stark contrast the difference between the fantasy Mobileye (NASDAQ:MBLY) targets of the analysts, and the reality for shareholders whose sentiments have been manipulated by the hype.

For the rest of the story you won't read anywhere else, Click Here …




Next Page »

3 queries in 1.250 seconds